View
484
Download
0
Category
Tags:
Preview:
Citation preview
EPA for prevention and treatment of bowel cancer
Professor Mark HullLeeds Institute of Biomedical & Clinical SciencesUniversity of Leeds and Leeds Teaching Hospitals
Bowel (colorectal) cancer
• Third most common cancer in men and women• Second commonest cause of cancer-related death• Treatment is sub-optimal and aggressive
– Bowel surgery– Chemotherapy– Radiotherapy
• But………..bowel cancer is preventable
Natural history of colorectal cancer
CRC liver metastasis
adenocarcinoma (cancer)adenoma (polyp)
benign malignant
5-10 years 0-5 years
1o CRC prevention strategies• Screening (stool testing, endoscopy)• Surveillance• Lifestyle/behaviour modification
– weight– diet– alcohol– smoking– awareness/early diagnosis
• Chemoprevention
Cancer chemoprevention
‘The use of natural or synthetic chemical agents to reverse, suppress, or prevent carcinogenic progression to invasive cancer’
Sporn 1976
The ideal CRC chemoprevention agent
• Effective– Colorectal cancer– Other malignancies– Other conditions (improved life-expectancy)
• Safe and well tolerated• Easy to use• Inexpensive
Candidate CRC chemoprevention agents
• omega-3 fatty acids• aspirin• other anti-inflammatories eg. ibuprofen • statins• metformin• calcium ± vitamin D• folate
Drug re-purposing
• The application of known drugs to a new disease• Advantages
– Well–established with excellent safety profile– Effectiveness against more than one condition– Inexpensive (off-patent)
• Disadvantages– Clinical testing can outstrip understanding of MOA– Off-patent (regulatory problems)
Aspirin goes ‘prime-time’
Colorectal cancer (CRC) prevention
CRC liver metastasis
adenocarcinoma (cancer)adenoma (polyp)
benign malignant1o and 2o chemoprevention 3o chemoprevention
seAFOod Trial The EMT2 Trial
aspirin
Omega-3 fatty acids (O3FAs)
• Found in highest quantities in oily fish (salmon or mackerel)• Two main long-chain O3FAs – EPA and DHA • 2 g daily dose = eating 10-12 portions of oily fish per week• ‘nutraceuticals’
– Concentrated (80-90%) EPA, DHA or EPA/DHA mix– Encapsulated– 2 g possible in 4-5 capsules– Minor gastrointestinal side-effects only (approx 5%)
• Large amount of experimental evidence that O3FAs have anti-cancer activity
Evidence that dietary O3FA intake reduces CRC risk is not convincing
• “Limited, but suggestive, evidence that dietary fish intake reduces CRC risk”• 35 cohort studies
• Approx. 50% have reported decreased risk
• >50 case-control studies • Meta-analysis of cohort studies
• RR for CRC 0.98 (0.88-1.09) in relation to O3FA intake
2nd Expert report WCRF/AICR 2007 and WCRF/AICR CUP 2011Br J Nutr 2012;108:1550-6
Strong pre-clinical evidence that O3FAs have CRC chemopreventative efficacy
• Chemical carcinogenesis models (15 rat/2 mouse)– 4-20% (v/w) fish oil in chow– 20-50% reduction in tumour incidence– 30-70% reduction in aberrant crypt focus/tumour
multiplicity
• ApcMin/+ and ApcD716 mouse models– 1-12% (v/w) fish oil in chow– 40-80% reduction in adenoma multiplicity
• Usually EPA/DHA mix• EPA = DHA
– 6 single w-3 PUFA studies– 1 direct comparison (ApcMin/+)
Gut 2012;61:135-49
Human biomarker studies of O3FA therapy
Gut 2012;61:135-149
Study(author/year)
DesignPatient group
N ω-3 PUFA daily dose Treatment Duration
Primary outcome
Mucosal PUFA content
Results
Anti 1992 R, DB, PC‘sporadic’ adenoma
24 7.7 g FO1 12 wk PI ↑EPA & ↓AA 62% ↓PI
Bartoli 1993 R, DB, PC‘sporadic’ adenoma
40 2.5-7.7 g FO1 30 days PI Dose dependent ↑EPA/DHA & ↓AA
Dose dependent 40-70%↓ PI
Bartram 1993 DB crossover trialHealthy volunteer
12 4.4 g FO2 4wk +4 wk PI ω-3 PUFA ω-6 PUFA↓( NS)
16%↓ PI & 35%↓ mucosal PGE2
Anti 1994 R, DB, PC ‘sporadic’ adenoma
60 2.5-7.7 g FO1 30 days PI Dose dependent ↑EPA/DHA & ↓AA
Dose independent 50-70%↓ PI
Huang 1996 R, DB, PCDukes A/B CRC or severely dysplastic polyp
27 7.2 g FO3 6 months PI ↑EPA/DHA & ↓AA 71%↓PI (only in patients with high baseline PI)
Gee 1999 R, PC, single blindAwaiting CRC surgery
51 2.4 g FO4 7-21 days pre- and 8-12 wk post- surgery
PI ↑EPA/DHA↑ ω-3 : ω-6 ratio
No effect on PI at surgery or 12wk post-op
Cheng 2003 R, C, open labelPrevious CRC/adenoma
41 Dietary advice +/- 500 mg FO5
2 years PI/AI Not assessed PI↔, 50%↑AI, 50%↑ Bax, COX2 ↔
Courtney 2007 R, single blind‘sporadic’ adenoma
30 EPA 2 g as FFA 3 months PI/AI ↑EPA/DHA & ↓AA 20%↓PI7x↑ AI
West 2009 R, DB, PC‘sporadic’ adenoma
152 EPA 1 g or2 g as FFA 6 months PI/AI ↑EPA/DHA & ↓AA 13%↓PI57%↑ AI (NS)
FO1 = 54%EPA/46% DHA as ethyl estersFO2 = 48%EPA/44%DHA, as triglyceridesFO3 = 55%EPA/30%DHA/15% other ω-3 PUFAsFO4 = 58% EPA/42%DHAFO5 = 20%EPA/80%DHA
-25
-20
-15
-10
-5
0
5
10
15
P = 0.0122
9.7 [-2.6; 22.0]
-12.6 [-24.7; -0.6]
-22.4 [-39.6; -5.1]
Δ No. of polyps (%)
Net changePlacebo EPA-FFA
EPA is chemopreventive in humans
Gut 2010;59:918-25
• double-blind randomised placebo-controlled trial of EPA 2g daily• 58 patients with familial adenomatous polyposis undergoing surveillance
The seAFOod (Systematic Evaluation of Aspirin and Fish Oil) polyp prevention trial
• Double-blind randomised placebo-controlled trial• 2 x 2 factorial design
– EPA 2 g daily (either FFA or TG) – aspirin EC 300 mg daily
• treatment for 12 months• NHS Bowel Cancer Screening Programme patients• Multiple polyp patients needing repeat colonoscopy at 1 year• No alteration of routine clinical practice• Tissue biobank• 51 sites in England• 550/755 (73%) recruited – recruitment end June 2016• Results available end of 2017
seAFOod Polyp Prevention Trial
placeboplacebo
placeboEPA 2g
aspirin 300mg placebo
aspirin 300mg EPA 2g
Different formulations of EPA
• 99% EPA-FFA 500 mg gastro-resistant capsules• 90% EPA-TG 574 mg soft-gel capsules (Igennus)• EPA-FFA dose equivalence
– 5 capsules 90% EPA-TG = 4 capsules 99% EPA-FFA– differences
• no gastro-resistant coating• small amount of AA
• Trial biobank to compare EPA bioavailability– RBCs, plasma, rectal mucosa
• So far…………no difference in adverse events or dropout
Pre-clinical evidence of EPA activity against CRC liver metastasis
EPA
DHA
AA
DPA
0
2
4
6
8
10
12
% P
UFA
co
nte
nt
CONTROL 2.5% EPA-FFA 5% EPA-FFA
0
1
2
3
4
5
Liv
er
we
igh
t (g
)
P<0.05
0
2000
4000
6000
8000
0
200
400
600
800
Tis
sue
PG
E2 (
pg
/mg
)
Tissu
e PG
E3 (p
g/m
g)
CONTROL 2.5% EPA-FFA 5% EPA-FFA
Br J Pharmacol 2012;166:1724-37
P=0.04
0
20
40
60
80
100
% B
rdU
-po
siti
ve
cel
ls
CONTROL 2.5% EPA-FFA 5% EPA-FFA
CONTROL 2.5% EPA-FFA 5% EPA-FFA
• A Phase II randomised double-blind placebo controlled trial of EPA 2 g daily in patients awaiting liver resection for liver metastasis
• ‘window trial’ - variable treatment period before surgery• Trial designed to test
• Safety and tolerability• Markers of tumour growth after surgical removal• Incorporation of EPA into tumour tissue• Survival after the trial had finished
The EPA for Metastasis Trial (EMT)
Gut 2014;63:1760-1768
Overall survival
Months
Per
cen
t su
rviv
al
0 6 12 18 24 30 36 420
25
50
75
100
Placebo
EPA
No. at risk
p=0.0985
Tumour fatty acid levels
PUFA Placebo (n=37)a EPA-FFA (n=37)a % difference from placebo
P value
EPA (C20:5w3) 1.30% (±0.10) 1.82% (±0.11) +40% 0.0008
DPA (C22:5w3) 1.25% (±0.08) 1.76% (±0.09) +41% <0.0001
DHA (C22:6w3) 2.89% (±0.12) 2.56%(±0.11) -11% 0.0465
AA (C20:4w6) 12.82% (±0.53) 12.03% (±0.45) -6% 0.2579
AA:EPA ratio 11.35 (±0.72) 7.58 (±0.53) -33% <0.0001
EPA
%
0
1
2
3
4
EPA-FFAplacebo
DPA
0
1
2
3
4
5
EPA-FFAplacebo
AA
%
0
5
10
15
20
25
EPA-FFAplacebo%
Gut 2014;63:1760-1768
• Compatible with tissue plasma membrane incorporation
• Rapid incorporation (2-3 weeks) but prolonged ‘washout’ over 3-4 months
• Is it explained by O3FA exposure during the critical peri-operative period?
• Decreased tumour growth and/or anti-cachexia mechanism?
Prolonged effect of short-term EPA-FFA therapy
• A Phase III randomised double-blind placebo controlled trial of EPA 2 g daily in patients awaiting surgery for liver metastasis
• treatment started before surgery then continuing for minimum 2 yr FU• Trial designed to test whether EPA provides survival benefit (30%
improvement)• 450 participants• 8 sites with high-volume liver surgery units• Leeds and Sheffield expected to contribute at least one third of patients• Measurement of EPA incorporation in patient samples• Start Oct 2015 – recruitment start Oct 2016• Results due 2020
The EMT2 trial
• RCT evidence that EPA has chemoprevention activity• seAFOod Trial will determine whether EPA ‘works’ in large
number of patients at risk of future CRC• Hint that EPA provides benefit in advanced CRC patients• EMT2 trial in patients with CRC liver metastasis just opening• Many open questions
– Optimal dose and timing?– Is it tissue EPA incorporation that matters?– EPA, DHA or both?– How does EPA have anti-cancer activity?
EPA for prevention and treatment of CRC
Acknowledgements (in no particular order!)
• patients• Co-Investigators• Collaborators• Trial staff• funders
Recommended